Patients receiving medications, herbal supplements, or food known to be moderate or strong inhibitors of CYP3A within 7 days prior to the first dose of M7583, or moderate or strong inducers of CYP3A within 21 days prior to the first dose of M7583, or drugs mainly metabolized by CYP3A with a narrow therapeutic index that cannot be stopped before the first dose of trial treatment.